Asheville Gastroenterology Associates has collaborated in both academic and pharmaceutical industry research since 1996. Our clinical research program works to provide access to new and innovative investigational treatments to adult patients with gastrointestinal and liver disorders. These programs are primarily research protocols designed to establish the safety and efficacy of new devices, drugs, or procedures in the course of obtaining FDA approval for their general use. Many of these research procedures benefit patients who otherwise do not have any available standard treatment options.
Our board certified gastroenterologists and full-time staff of trained and certified clinical research coordinators work with the pharmaceutical industry and academic medical centers to conduct these trials. We participate in phase II, III, and IV clinical trials. Asheville Gastroenterology Associates is committed to conducting quality research and maintaining good clinical practice (GCP) standards.
We have participated in more than 100 drug and device trials, as well as serving as an adjunct site in collaboration with academic medical centers. These studies have reflected the spectrum of gastrointestinal and liver diseases including clinical trials for gastroesophageal reflux disease, constipation, colon purgatives, dyspepsia, sedation medications for colonoscopy, colon cancer prevention, blood tests for detecting colon cancer, Crohn’s, ulcerative colitis, proctitis, irritable bowel syndrome, clostridium difficile colitis, celiac disease, encephalopathy, variceal bleeding, hepatitis C, hepatitis B, fatty liver, ascites, and drug-induced liver injury.
Asheville Gastroenterology Associates plans to continue participating in clinical trials utilizing our patient data base which consists of over 57,000 annual patient encounters and 165,000 active medical records. Our research department located at our main Asheville office is computerized to insure the accuracy of data collection and to maintain a patient database for future clinical trials.